Articles tagged with Multiple Sclerosis
A new collaborative study from the Mayo Clinic and Cleveland Clinic suggests that multiple sclerosis may progress from the outermost layers of the brain to its deep parts. The researchers found that the cortex is involved early in MS and may even be the initial target of disease.
A study published in the American Journal of Pathology suggests laquinimod targets immune cells to increase neuroprotection in multiple sclerosis patients. The treatment increases brain-derived neurotrophic factor (BDNF) levels, contributing to neuron repair and limiting brain damage.
Neuromyelitis optica (NMO) is an inflammatory autoimmune disease that damages optic nerves and spinal cord. Mayo Clinic researchers have identified critical steps leading to myelin destruction, which could lead to better diagnosis and treatment of the disease.
A University at Buffalo study of 252 volunteers identified an association between chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS) risk factors, including infectious mononucleosis, irritable bowel syndrome, and smoking. The findings suggest that CCSVI may be a vascular condition similar to MS, warranting f...
A modified Story Memory Technique was found to be effective in improving learning and memory deficits in people with multiple sclerosis. The treatment group showed greater activation in a widespread cortical network, indicating improved cognitive function.
Two Kessler Foundation researchers received over $100,000 in National Multiple Sclerosis Society grants to investigate cognitive impairments in MS. The studies aim to improve processing speed and understand the relationship between white matter damage and cognitive decline.
Researchers have discovered that connexin 36 protects mouse pancreatic beta-cells against immune molecules prevalent in type 1 diabetes. Additionally, a study found that PTHrP drives breast tumor initiation, progression, and metastasis in mice, suggesting it as a potential therapy target.
Researchers discovered that crocin in saffron exerts protective effects on brain cells and prevented damage in models of MS. The study also found a link between an ancient virus and cell stress leading to inflammation in the disease.
The study found that Ocrelizumab led to a 89% reduction in brain lesions and reduced the number of new multiple sclerosis attacks over 24 weeks. This suggests targeting B cells could help treat MS.
Research suggests that natural intestinal flora may play a crucial role in the emergence of multiple sclerosis. Beneficial bacteria can activate immune cells and trigger an overreaction of the immune system in genetically predisposed individuals. This finding has important implications for disease prevention and treatment.
Scientists have developed a sensor array that can diagnose multiple sclerosis from exhaled breath, offering a fast, inexpensive and non-invasive alternative to traditional methods. The technology has been tested in humans and shows promising results, rivaling the accuracy of spinal taps without pain or risk.
A potential new drug target has been discovered to stop debilitating effects of MS by preventing brain cell death caused by granzyme B. The target is the M6PR receptor, which allows granzyme B to enter neurons and wreak havoc.
A six-month randomized controlled trial found no added benefit from high-dose vitamin D over and above ongoing low-dose vitamin D supplementation in treating relapsing-remitting multiple sclerosis. The study involved 23 participants with MS, who received either high-dose or placebo high-dose vitamin D, and showed no significant differe...
Research suggests that shift work in teenagers may increase the risk of developing multiple sclerosis, a central nervous system autoimmune inflammatory disorder. Disruption of the circadian rhythm and sleep patterns are believed to contribute to this increased risk.
A team from the University of Utah has received a $275,000 NIH grant to study brain tissue from patients with primary progressive multiple sclerosis (PPMS) using advanced technology called deep sequencing. The goal is to identify viruses that might play a role in the development of PPMS and potentially lead to new treatments.
A new oral drug, teriflunomide, has been shown to significantly reduce the relapse rate of people with multiple sclerosis and slow the progression of the disease. The drug was found to be effective in increasing the time between relapses and reducing disease progression by almost 30%.
A systematic review found that taking natalizumab for two years lowers the number of MS patients who experience relapses and progression of disability. The medication also delays disease progression, according to MRI brain scans.
A review of eight studies found an association between chronic cerebrospinal venous insufficiency and multiple sclerosis, but poor study quality and inconsistencies hinder definitive conclusions. Further research is needed to clarify the relationship.
A meta-analysis found a strong association between CCSVI and multiple sclerosis, but the low quality of included studies prevents a definitive conclusion. The variation in study results suggests that factors such as sample size, ultrasound techniques, and training of operators may contribute to the heterogeneity.
A glucosamine-like dietary supplement, N-acetylglucosamine (GlcNAc), suppresses multiple sclerosis attacks by inhibiting abnormal T-cell growth and function. The study, published in The Journal of Biological Chemistry, suggests a novel mechanism for affecting T-cell function and autoimmunity.
Researchers at University of California - San Diego have discovered that inhibiting a single enzyme helps slow disease progression in a mouse model of multiple sclerosis. The study suggests that targeting fatty acid metabolism could lead to new therapies with fewer side effects.
Researchers at Cleveland institutions collaborate on a ground-breaking study testing the feasibility and safety of using mesenchymal stem cells to treat multiple sclerosis. The Phase 1 trial aims to decrease disease activity and promote repair in patients with MS.
A recent study by Yale University researchers has identified more than two dozen new genetic variants linked to disease risk in multiple sclerosis and other autoimmune diseases. The findings suggest a common genetic basis for many devastating immune system disorders.
Researchers identified 29 new genetic variants linked to multiple sclerosis, shedding light on immunological pathways and immune system involvement. The study confirms 23 known genetic associations and provides insight into a possible link between genetic and environmental risk factors.
An international team of scientists identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of the disease. The study confirms 23 previously known genetic associations and doubles the number of genes associated with MS.
A large international study has identified 29 new genetic variants associated with multiple sclerosis, providing key insights into the biology of the disease. The research highlights the pivotal role of the immune system in causing damage and helps explain the nature of the immune attack on the brain and spinal cord.
A study analyzed data from 844 individuals with early-stage Multiple Sclerosis and found that disease-modifying drugs provide modest health gains, but their cost is more than 8 times higher than considered reasonable. The study's authors highlight the need to reevaluate treatment costs to control healthcare expenses.
A new study examines the cost-effectiveness of MS drugs in the US, finding that they come at a high cost compared to basic therapy and other chronic diseases. The research suggests that reducing medication prices by 67% could improve the cost-benefit ratio and support earlier disease-modifying therapy.
People with multiple sclerosis are at risk of poor bone health in the early stages of the disease, with 51% experiencing osteoporosis or osteopenia. Low vitamin D levels can lead to reduced calcium absorption and bone mineralization.
New research from the American Academy of Neurology found that breastfeeding does not have a protective effect on multiple sclerosis relapses. In fact, women with high disease activity and high risk of postpartum relapses may need to resume MS treatment after giving birth.
A team of researchers has discovered a naturally occurring disease in monkeys that shares similarities with multiple sclerosis, providing new insights into the cause of the disease. The discovery is associated with a herpes virus and could lead to significant advancements in MS research and treatment.
Researchers analyzed data from BC MS Clinics' database and BC Perinatal Database Registry to compare pregnancy outcomes in women with MS to those without the disease. Babies born to mothers with MS did not have significantly different gestational age or birth weight, but mothers with greater disability had slightly elevated risk of adv...
A Rush University Medical Center scientist is studying cinnamon's effects on multiple sclerosis, a disease that attacks the central nervous system. The research aims to understand how cinnamon's anti-inflammatory property may counteract the disease process in mice.
Scientists at The University of Nottingham have discovered a synthetic chemical compound that reduces MS severity by inhibiting pro-inflammatory signals while stimulating interferon-beta production. The findings highlight a potential new mechanism for treating the chronic inflammatory disease, which affects over 100,000 people in the UK.
A multidisciplinary panel recommends careful, well-designed research on chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. The goal is to evaluate the role of vein widening with angioplasty and potential stent placement in improving symptoms.
A study at The University of Nottingham found that group therapy sessions can reduce anxiety and depression in MS patients, improving their quality of life. The treatment reduced costs for the NHS by almost £470 per patient, with savings also seen in GP visits and outpatient hospital costs.
Researchers have found that shingles may be associated with an increased risk of developing multiple sclerosis, particularly in the year following a shingles attack. The study suggests that this risk is still relatively low and varies by geographical location and income.
Researchers at UCI have identified a unifying mechanism responsible for multiple sclerosis, suggesting personalized therapies based on genetic factors. Vitamin D3 and GlcNAc supplements can reverse the effects of four human MS genetic factors, restoring normal protein modification and potentially treating the disease.
A recent study published in Neurology found that stress does not increase the risk of developing multiple sclerosis. Researchers studied two groups of nurses and found no significant link between severe stress at home or during childhood and adolescence and the development of MS.
African Americans with multiple sclerosis have lower vitamin D levels than those without the disease. The study suggests low vitamin D may be a risk factor for developing multiple sclerosis, but other factors such as genes and environmental triggers also play a role in disease severity.
Vitamin D deficiency is prevalent among African-American patients with MS, largely due to regional UV exposure and geographic factors. Low vitamin D levels were found in nearly 77% of MS patients compared to 71% without the disease.
Researchers at UC Santa Barbara developed a new method of nanoscopic imaging that could lead to early detection and diagnosis of multiple sclerosis. The study focused on the myelin sheath, a membrane surrounding nerves compromised in MS patients.
Researchers discovered that Viagra reduces multiple sclerosis symptoms by reducing inflammation and facilitating myelin repair. A daily treatment resulted in a 50% practically complete recovery rate in animal models with the disease.
Researchers at University of Granada analyzed antibody levels in patients with multiple sclerosis and found a statistically significant association between viral infection markers and the condition. Further research is needed to confirm the link.
Researchers have created a new X-ray method called SAXS-CT to map the myelin sheaths of nerve cells in detail. This can provide insights into neurodegenerative diseases such as cerebral malaria, multiple sclerosis, and Alzheimer's disease.
Researchers discovered that estrogen receptors in the brain help turn off genes leading to chronic inflammation. This finding may lead to new treatments for multiple sclerosis and other neurodegenerative conditions.
A paper in Nature notes the power of social media in shaping research priorities in Canada, particularly in the case of a controversial multiple sclerosis treatment. Researchers call for more effective communication tools between scientists and the public to ensure patients' concerns are heard.
Researchers found GM-CSF crucial for MS disease progression, neutralizing it could reverse inflammation. A clinical trial is set to launch this year to test GM-CSF neutralization in patients.
Researchers have identified GM-CSF as a driving force behind autoimmune diseases like MS. Blocking its activity may lead to new treatments for the disease. Dr. Abdolmohamad Rostami and his team found that GM-CSF is responsible for disease manifestation in an experimental animal model.
Researchers found a strong association between low sunlight exposure and an increased risk of developing multiple sclerosis (MS) in people who have had infectious mononucleosis. The study, published in the April 2011 issue of Neurology, suggests that vitamin D deficiency may play a role in this association.
A newly developed compound, SR1001, has been shown to effectively suppress the severity of multiple sclerosis in animal models with minimal side effects. The discovery holds promise for treating other autoimmune diseases and targets a specific cell type involved in autoimmunity.
Researchers found that a subgroup of PPMS patients can convert to PRMS, with faster disease progression and increased risk for sustained disability. The study emphasizes the need for clinicians to consider evaluating this subgroup differently in assessing prognosis and clinical course.
A recent study found that chronic cerebral venous insufficiency (CCSVI) is more prevalent in multiple sclerosis (MS) patients, particularly those with progressive forms of the disease. The research suggests CCSVI may be a consequence of MS progression rather than a cause, warranting further investigation.
Researchers at Mayo Clinic have created a tool that uses cerebrospinal fluid test results to predict disability timelines for patients with progressive multiple sclerosis. The study found that patients with higher levels of certain proteins in their CSF are more likely to experience a faster onset of disability.
A Phase III clinical study found that laquinimod reduced annual relapse rates by 23% and disability progression by 36%. Laquinimod also slowed brain atrophy by 33%. The study involved 1,106 people with relapsing-remitting MS in 24 countries.
Researchers found that people who used marijuana performed significantly worse in attention, speed of thinking, executive function, and visual perception, with some scoring approximately one third lower than non-users. The study suggests that prolonged marijuana use may add to the cognitive burden already experienced by MS patients.
Researchers have shown that angioplasty to widen internal jugular and azygos veins is safe for multiple sclerosis patients. The treatment improved blood flow and reduced symptoms in 97% of patients with no significant complications.
Scientists have discovered a previously unknown type of axonal degeneration called focal axonal degeneration (FAD), which is responsible for damage to nerve cells in multiple sclerosis. FAD can be reversed if recognized and treated early, suggesting a potential target for therapeutic intervention.
A long-term study reports the effectiveness of stem cell transplants in replacing bone marrow and reducing disease activity in people with rapidly progressive MS. The treatment showed promising results, with an average improvement in symptoms lasting two years.
A study published in Neurology has found that children with a specific gene variation are at higher risk of developing Multiple Sclerosis. The research identifies the HLA-DRB1 allele as a key factor in pediatric-onset MS, which can provide insights into disease causes and potentially lead to earlier diagnoses and new therapies.